Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors

Nature Medicine

Volumn 11, Issue 7, 2005, Pages 774-779

  Idris, Aymen I ^a,c   Van't Hof, Robert J ^a,c   Greig, Iain R ^a   Ridge, Susan A ^a   Baker, David ^b   Ross, Ruth A ^a   Ralston, Stuart H ^a,c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MASS; BONE TURNOVER; CELL ACTIVITY; CONTROLLED STUDY; DRUG EFFECT; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RECEPTOR DOWN REGULATION;

ANIMALS; APOPTOSIS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; BORNANES; CARRIER PROTEINS; CELLS, CULTURED; FEMALE; INDOLES; LIGANDS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOCLASTS; OVARIECTOMY; PIPERIDINES; PYRAZOLES; RABBITS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

ANIMALIA;

EID: 22544439953     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1255     Document Type: Article

References (24)

1. Teitelbaum, S.L. Bone resorption by osteoclasts. Science 289, 1504-1508 (2000).
2. Helfrich, M.H. Osteoclast diseases. Microsc. Res. Tech. 61, 514-532 (2003).
3. Rodan, G.A. & Martin, T.J. Therapeutic approaches to bone diseases. Science 289, 1508-1514 (2000).
4. Khosla, S. Minireview: The OPG/RANKL/RANK System. Endocrinology 142, 5050-5055 (2001).
5. Baldock, P.A. et al. Hypothalamic Y2 receptors regulate bone formation. J. Clin. Invest. 109, 915-921 (2002).
6. Skerry, T.M. & Genever, P.G. Glutamate signalling in non-neuronal tissues. Trends Pharmacol. Sci. 22, 174-181 (2001).
7. van't Hof, R.J., Macphee, J., Libouban, H., Helfrich, M.H. & Ralston, S.H. Regulation of bone mass and bone turnover by neuronal nitric oxide synthase. Endocrinology 145, 5068-5074 (2004).
8. Ducy, P. et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100, 197-207 (2000).
9. Takeda, S. et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 111, 305-317 (2002).
10. Pertwee, R.G. & Ross, R.A. Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fatty Acids 66, 101-121 (2002).
11. Ravinet, T.C. et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R345-R353 (2003).
12. Shearman, L.P. et al. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav. Pharmacol. 14, 573-582 (2003).
13. Hildebrandt, A.L., Kelly-Sullivan, D.M. & Black, S.C. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur. J. Pharmacol. 462, 125-132 (2003).
14. Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889-901 (2002).
15. David, J.P., Sabapathy, K., Hoffmann, O., Idarraga, M.H. & Wagner, E.F. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation- dependent and -independent mechanisms. J. Cell Sci. 115, 4317-4325 (2002).
16. Grigoriadis, A.E. et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266, 443-448 (1994).
17. Hewlett, A.C. et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol. Rev. 54, 161-202 (2002).
18. Takahashi, N., Udagawa, N., Tanaka, S. & Suda, T. Generating murine osteoclasts from bone marrow. Methods Mol. Med. 80, 129-144 (2003).
19. Coxon, F.P. et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J. Bone Miner. Res. 15, 1467-1476 (2000).
20. van't Hof, R.J. et al. Identification of biphenylcarboxylic acid derivatives as a novel class of bone resorption inhibitors. J. Bone Miner. Res. 19, 1651-1660 (2004).
21. Hewlett, A.C., Song, C., Berglund, B.A., Wilken, G.H. & Pigg, J.J. Characterization of CB1 cannabinoid receptors using receptor peptide fragments and site-directed antibodies. Mol. Pharmacol. 53, 504-510 (1998).
22. Casanova, M.L. et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest. 111, 43-50 (2003).
23. Pryce, G. et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126, 2191-2202 (2003).
24. Armour, K.E. et al. Defective bone formation and anabolic responses to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide sythase. Endocrinology 142, 760-766 (2001).